10 Result(s)
within
Shyamala Maheswaran
Oncology
-
Article
Open AccessModeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
Metastatic hormone receptor-positive (HR+) breast cancer initially responds to serial courses of endocrine therapy, but ultimately becomes refractory. Elacestrant, a new generation FDA-approved oral selective ...
-
Article
Open AccessDownregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Immune checkpoint blockade (ICB) has demonstrated efficacy in patients with melanoma, but many exhibit poor responses. Using single cell RNA sequencing of melanoma patient-derived circulating tumor cells (CTCs...
-
Article
Evaluation of endocrine resistance using ESR1 genoty** of circulating tumor cells and plasma DNA
Therapeutic efficacy of hormonal therapies to target estrogen receptor (ER)-positive breast cancer is limited by the acquisition of ligand-independent ESR1 mutations, which confer treatment resistance to aromatas...
-
Chapter
Quantitative Analysis of Circulating Tumor Cells Using RNA-Based Digital Scoring
Circulating tumor cells (CTCs) provide valuable information about the molecular evolution of cancers, as they may initially respond and ultimately progress on therapy. As intact tumor cells isolated from the b...
-
Article
Open AccessBlood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
Plasma genoty** identifies potentially actionable mutations at variable mutant allele frequencies, often admixed with multiple subclonal variants, highlighting the need for their clinical and functional vali...
-
Article
Open AccessRelationship between hepatocellular carcinoma circulating tumor cells and tumor volume
Microfluidic platforms have demonstrated the ability to isolate rare circulating tumor cells from a wide variety of cancers. Our group has recently shown the ability to isolate circulating tumor cells (CTCs) f...
-
Article
Open AccessBevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication
Homeobox B9 (HOXB9), a transcriptional factor, regulates developmental processes and tumor progression and has recently been recognized as one of important transcriptional factors related to angiogenesis. This...
-
Article
Expression of the NF-κB-responsive gene BTG2 is aberrantly regulated in breast cancer
BTG2, a p53-inducible antiproliferative gene, is stimulated in breast cancer cells by activation of nuclear factor kappa B (NF-κB). In rat mammary glands, BTG2 is expressed in epithelial cells and levels decrease...
-
Article
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents
BRCA1 is a tumour suppressor gene implicated in the predisposition to early onset breast and ovarian cancer. We have generated cell lines with inducible expression of BRCA1 to evaluate its role in mediating th...
-
Article
E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells
WT1 encodes a tumor suppressor that is expressed in cells of the develo** kidney and is inactivated in Wilms tumor, a pediatric kidney cancer. The adenovirus E1B 55K gene product contributes to the transformati...
